Cagrilintide
Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide. Research A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits. References

Amylin receptor agonists Experimental diabetes drugs Cyclic peptides Peptide therapeutics {{gastrointestinal-drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]